Fumihiro Tanaka

832 total citations · 1 hit paper
12 papers, 146 citations indexed

About

Fumihiro Tanaka is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Fumihiro Tanaka has authored 12 papers receiving a total of 146 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 6 papers in Oncology and 3 papers in Surgery. Recurrent topics in Fumihiro Tanaka's work include Lung Cancer Diagnosis and Treatment (5 papers), Gastric Cancer Management and Outcomes (4 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Fumihiro Tanaka is often cited by papers focused on Lung Cancer Diagnosis and Treatment (5 papers), Gastric Cancer Management and Outcomes (4 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Fumihiro Tanaka collaborates with scholars based in Japan, United States and Canada. Fumihiro Tanaka's co-authors include Mark M. Awad, Shun Lü, Janis M. Taube, Jie He, Padma Sathyanarayana, Robin Cornelissen, Libor Havel, S. Meadows–Shropshire, Tina Cascone and Boris Sepesi and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Fumihiro Tanaka

10 papers receiving 145 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC

2023 67 citations Tina Cascone, Mark M. Awad et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Fumihiro Tanaka Japan	7	132	98	24	16	16	12	146
Mike Aperghis Japan	5	133 1.0×	117 1.2×	8 0.3×	23 1.4×	11 0.7×	5	156
Elodie Amour France	6	136 1.0×	77 0.8×	13 0.5×	12 0.8×	13 0.8×	14	160
John Wen-Cheng Chang Taiwan	6	88 0.7×	82 0.8×	15 0.6×	13 0.8×	16 1.0×	8	121
Nivedita Aanur United States	5	108 0.8×	149 1.5×	13 0.5×	24 1.5×	3 0.2×	6	164
J. Casal Rubio Spain	4	103 0.8×	110 1.1×	3 0.1×	11 0.7×	5 0.3×	13	121
Srushti Shah India	5	66 0.5×	30 0.3×	14 0.6×	29 1.8×	4 0.3×	12	79
A. Li United States	6	101 0.8×	142 1.4×	13 0.5×	12 0.8×	3 0.2×	13	149
E. Felip Font Spain	6	77 0.6×	89 0.9×	9 0.4×	8 0.5×	7 0.4×	15	109
G. Oliviéro France	7	98 0.7×	73 0.7×	22 0.9×	10 0.6×	6 0.4×	15	135

Countries citing papers authored by Fumihiro Tanaka

Since Specialization

Citations

This map shows the geographic impact of Fumihiro Tanaka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fumihiro Tanaka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fumihiro Tanaka more than expected).

Fields of papers citing papers by Fumihiro Tanaka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fumihiro Tanaka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fumihiro Tanaka. The network helps show where Fumihiro Tanaka may publish in the future.

Co-authorship network of co-authors of Fumihiro Tanaka

This figure shows the co-authorship network connecting the top 25 collaborators of Fumihiro Tanaka. A scholar is included among the top collaborators of Fumihiro Tanaka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fumihiro Tanaka. Fumihiro Tanaka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Kanayama, Masatoshi, Shinji Shinohara, Taiji Kuwata, et al.. (2025). Predictors of successful closure following open-window thoracostomy in patients with empyema: a single-center retrospective cohort study. Journal of Thoracic Disease. 17(5). 3138–3146.

Kanayama, Masatoshi, et al.. (2025). Immune checkpoint inhibitors in the treatment of pleural mesothelioma: insights from real-world data. International Journal of Clinical Oncology. 30(4). 705–717. 2 indexed citations

Deutsch, Julie S., Ashley Cimino‐Mathews, Elizabeth D. Thompson, et al.. (2025). Abstract CT097: Associations between percent residual viable tumor (%RVT) and efficacy with perioperative nivolumab (NIVO) for resectable NSCLC in CheckMate 77T. Cancer Research. 85(8_Supplement_2). CT097–CT097.

Cascone, Tina, Mark M. Awad, Jonathan Spicer, et al.. (2025). Perioperative nivolumab (NIVO) vs placebo (PBO) in patients (pts) with resectable NSCLC: Updated survival and biomarker analyses from CheckMate 77T.. Journal of Clinical Oncology. 43(17_suppl). 4 indexed citations

Forde, Patrick M., Jonathan Spicer, Mariano Provencio, et al.. (2025). Overall survival with neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816.. Journal of Clinical Oncology. 43(17_suppl). 2 indexed citations

Spicer, Jonathan, Nicolas Girard, Mariano Provencio, et al.. (2024). Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816.. Journal of Clinical Oncology. 42(17_suppl). LBA8010–LBA8010. 25 indexed citations

Provencio, Mariano, Mark M. Awad, Jonathan Spicer, et al.. (2024). Clinical outcomes with perioperative nivolumab (NIVO) by nodal status among patients (pts) with stage III resectable NSCLC: Results from the phase 3 CheckMate 77T study.. Journal of Clinical Oncology. 42(17_suppl). LBA8007–LBA8007. 9 indexed citations

Cascone, Tina, Mark M. Awad, Jie He, et al.. (2023). LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC. Annals of Oncology. 34. S1295–S1295. 67 indexed citations breakdown →

Spicer, Jonathan, Patrick M. Forde, Mariano Provencio, et al.. (2023). Clinical outcomes with neoadjuvant nivolumab (N) + chemotherapy (C) vs C by definitive surgery in patients (pts) with resectable NSCLC: 3-y results from the phase 3 CheckMate 816 trial.. Journal of Clinical Oncology. 41(16_suppl). 8521–8521. 13 indexed citations

10.

Girard, Nicolas, Jonathan Spicer, Mariano Provencio, et al.. (2022). Abstract CT012: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment for resectable (IB-IIIA) non-small cell lung cancer (NSCLC): Event-free survival (EFS) results from the phase 3 CheckMate 816 trial. Cancer Research. 82(12_Supplement). CT012–CT012. 6 indexed citations

11.

Shimokawa, Mototsugu, Seiki Hasegawa, K. Fukuoka, et al.. (2013). A Feasibility Study of Induction Pemetrexed Plus Cisplatin Followed by Pleurectomy/Decortication Aimed at Macroscopic Complete Resection for Malignant Pleural Mesothelioma. Japanese Journal of Clinical Oncology. 43(5). 575–578. 7 indexed citations

12.

Hashimoto, Motomu, et al.. (2013). 090 * SIGNIFICANT INCREASE IN CIRCULATING TUMOUR CELLS IN PULMONARY VENOUS BLOOD DURING SURGICAL MANIPULATION IN PATIENTS WITH PRIMARY LUNG CANCER. Interactive Cardiovascular and Thoracic Surgery. 17(suppl 2). S91–S91. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact